VEGFA and melanoma: Complementary studies in the same mouse strain demonstrated VEGF-specific cellular responses capable of efficiently lysing B16-F10 melanoma cells ex vivo showing a marked 75% reduction (Figure 1I, mean difference: -1230 ± 508.6%, 95% CI [-2363 to -96.81], p=0.0362, unpaired t-test).